51.58Open48.50Pre Close3 Volume52 Open Interest200.00Strike Price15.06KTurnover0.00%IV1.10%PremiumJan 17, 2025Expiry Date46.27Intrinsic Value100Multiplier-2DDays to Expiry2.72Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet